[go: up one dir, main page]

RU2223760C2 - Способы профилактики и лечения, применение усилителей чувствительности к инсулину - Google Patents

Способы профилактики и лечения, применение усилителей чувствительности к инсулину Download PDF

Info

Publication number
RU2223760C2
RU2223760C2 RU2002104459/14K RU2002104459K RU2223760C2 RU 2223760 C2 RU2223760 C2 RU 2223760C2 RU 2002104459/14 K RU2002104459/14 K RU 2002104459/14K RU 2002104459 K RU2002104459 K RU 2002104459K RU 2223760 C2 RU2223760 C2 RU 2223760C2
Authority
RU
Russia
Prior art keywords
group
formula
enhancer
inhibitor
mammal
Prior art date
Application number
RU2002104459/14K
Other languages
English (en)
Inventor
Хитоси ИКЕДА (JP)
Хитоси ИКЕДА
Такаси СОХДА (JP)
Такаси СОХДА
Хироюки ОДАКА (JP)
Хироюки ОДАКА
Original Assignee
Такеда Кемикал Индастриз, Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15563926&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2223760(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Такеда Кемикал Индастриз, Лтд. filed Critical Такеда Кемикал Индастриз, Лтд.
Application granted granted Critical
Publication of RU2223760C2 publication Critical patent/RU2223760C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Изобретение относится к медицине, в честности к эндокринологии, и касается лечения сахарного диабета и осложнений, связанных с диабетом. Для этого предлагают вводить препарат из группы усилителей чувствительности к инсулину, исключая троглитазон, в сочетании с препаратом из группы усилителей секреции инсулина, а также выбранном из ингибиторов альфа-глюкозидазы, ингибиторов альфа-редуктазы, бигуанидов, статиновых соединений, ингибиторов синтеза сквалена, фибратных соединений, усилителей катаболизма ЛНП и ингибиторов АПФ. Сочетания этих препаратов вводят также в виде смеси. Указанные сочетания, помимо гипогликемического эффекта, обеспечивают снижение веса, концентрации триглицеридов в плазме крови, неожиданно высокую активность в отношении снижения концентрации глюкозы в крови при сохранении дозы усилителя чувствительности к инсулину. 2 с. и 10 з.п. ф-лы, 5 табл.

Description

Текст описания в факсимильном виде (см. графическую часть)т

Claims (12)

1. Способ профилактики или лечения диабета или связанных с ним осложнений у нуждающегося в этом млекопитающего, отличающийся тем, что он включает введение указанному млекопитающему усилителя чувствительности к инсулину (исключая троглитазон) в сочетании с по меньшей мере одним членом из группы, включающей ингибитор альфа-глюкозидазы, ингибитор альдозоредуктазы, бигуанид, статиновое соединение, ингибитор синтеза сквалена, фибратное соединение, усилитель катаболизма липопротеинов низкой плотности (ЛНП) и ингибитор ангиотензинпревращающего фермента.
2. Способ по п.1, отличающийся тем, что усилитель чувствительности к инсулину представляет собой соединение, формулы
Figure 00000045
где R представляет собой возможно замещенную углеводородную или гетероциклическую группу;
Y представляет собой группу формулы -СО-, -СН(ОН)- или -NR3- (где R3 представляет собой возможно замещенную алкильную группу);
m = 0 или 1;
n = 0, 1 или 2;
Х представляет собой СН или N;
А представляет собой связь или С1-7 двухвалентную алифатическую углеводородную группу;
Q представляет собой атом кислорода или серы;
R1 представляет собой атом водорода или алкильную группу;
кольцо Е может иметь от 1 до 4 заместителей, причем заместители могут быть соединены с R1 с образованием кольца;
L и М соответственно представляют собой атом водорода или L и М могут быть соединены друг с другом с образованием связи,
или его фармакологически приемлемую соль.
3. Способ по п.2, отличающийся тем, что соединение, представленное формулой (I), представляет собой пиоглитазон.
4. Способ по п.2, отличающийся тем, что соединение, представленное формулой (I), представляет собой BRL-49653.
5. Способ по любому из пп.1 и 2, отличающийся тем, что усилитель чувствительности к инсулину смешан с по меньшей мере одним членом из группы, включающей ингибитор альфа-глюкозидазы, ингибитор альдозоредуктазы, бигуанид, статиновое соединение, ингибитор синтеза сквалена, фибратное соединение, усилитель катаболизма ЛНП и ингибитор ангиотензинпревращающего фермента с образованием смеси и данную смесь вводят млекопитающему.
6. Способ по любому из пп.1 и 2, отличающийся тем, что усилитель чувствительности к инсулину (исключая троглитазон) и по меньшей мере один член из группы, включающей ингибитор альфа-глюкозидазы, ингибитор альдозо-редуктазы, бигуанид, статиновое соединение, ингибитор синтеза сквалена, фибратное соединение, усилитель катаболизма ЛНП и ингибитор ангиотензинпревращающего фермента, не смешивают вместе, а вводят млекопитающему независимо.
7. Способ профилактики или лечения диабета или связанных с ним осложнений у нуждающегося в этом млекопитающего, отличающийся тем, что он включает введение указанному млекопитающему соединения, представленного формулой
Figure 00000046
где R` представляет собой возможно замещенную углеводородную или гетероциклическую группу;
Y представляет собой группу формулы -СО-, -СН(ОН)- или -NR3- (где R3 представляет собой возможно замещенную алкильную группу);
m = 0 или 1;
n = 0, 1 или 2;
Х представляет собой СН или N;
А представляет собой связь или С1-7 двухвалентную алифатическую углеводородную группу;
Q представляет собой атом кислорода или серы;
R1 представляет собой атом водорода или алкильную группу;
кольцо Е может иметь от 1 до 4 заместителей, причем заместители могут быть объединены с R1 с образованием кольца;
L и М соответственно представляют собой атом водорода или L и М могут быть обьединены друг с другом с образованием связи;
при условии, что R' не является бензопиранильной группой, когда m и n = 0, Х представляет собой СН, А представляет собой связь, Q представляет атом серы, R1, L и М представляют собой атом водорода, а кольцо Е не имеет дополнительных заместителей,
или его фармакологически приемлемую соль (исключая троглитазон) в сочетании с усилителем секреции инсулина.
8. Способ по п.7, отличающийся тем, что соединение, представленное формулой (II), представляет собой пиоглитазон.
9. Способ по п.7, отличающийся тем, что соединение, представленное формулой (II), представляет собой BRL-49653.
10. Способ по п.7, отличающийся тем, что усилитель секреции инсулина представляет собой сульфонилмочевину.
11. Способ по п.7, отличающийся тем, что соединение, представленное формулой (II), и усилитель секреции инсулина смешивают вместе с образованием смеси и смесь вводят млекопитающему.
12. Способ по п.7, отличающийся тем, что соединение, представленное формулой (II), и усилитель секреции инсулина не смешивают вместе, а вводят млекопитающему независимо.
RU2002104459/14K 1995-06-20 1996-06-19 Способы профилактики и лечения, применение усилителей чувствительности к инсулину RU2223760C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP15350095 1995-06-20
JP07-153500 1995-06-20

Publications (1)

Publication Number Publication Date
RU2223760C2 true RU2223760C2 (ru) 2004-02-20

Family

ID=15563926

Family Applications (5)

Application Number Title Priority Date Filing Date
RU96111958/14K RU2198682C2 (ru) 1995-06-20 1996-06-19 Фармацевтическая композиция
RU2002104459/63A RU2327455C2 (ru) 1995-06-20 1996-06-19 Способы профилактики и лечения, применение усилителей чувствительности к инсулину
RU2002104459/14K RU2223760C2 (ru) 1995-06-20 1996-06-19 Способы профилактики и лечения, применение усилителей чувствительности к инсулину
RU96111958/63A RU2323004C2 (ru) 1995-06-20 1996-06-19 Фармацевтическая композиция
RU2003130978/14A RU2286148C2 (ru) 1995-06-20 2003-10-20 Способы профилактики и лечения, применение усилителей чувствительности к инсулину

Family Applications Before (2)

Application Number Title Priority Date Filing Date
RU96111958/14K RU2198682C2 (ru) 1995-06-20 1996-06-19 Фармацевтическая композиция
RU2002104459/63A RU2327455C2 (ru) 1995-06-20 1996-06-19 Способы профилактики и лечения, применение усилителей чувствительности к инсулину

Family Applications After (2)

Application Number Title Priority Date Filing Date
RU96111958/63A RU2323004C2 (ru) 1995-06-20 1996-06-19 Фармацевтическая композиция
RU2003130978/14A RU2286148C2 (ru) 1995-06-20 2003-10-20 Способы профилактики и лечения, применение усилителей чувствительности к инсулину

Country Status (26)

Country Link
US (44) US5952356A (ru)
EP (6) EP0749751A3 (ru)
JP (3) JP3148973B2 (ru)
KR (3) KR970000233A (ru)
CN (3) CN1530106A (ru)
AR (4) AR005641A1 (ru)
AT (2) ATE438397T1 (ru)
CA (3) CA2533845C (ru)
CY (4) CY2424B1 (ru)
CZ (2) CZ291624B6 (ru)
DE (4) DE69631157T2 (ru)
DK (2) DK1174135T3 (ru)
ES (2) ES2327383T5 (ru)
FR (1) FR09C0055I2 (ru)
HK (2) HK1010484A1 (ru)
HU (1) HUP9601698A3 (ru)
LU (2) LU91298I2 (ru)
MX (1) MX9602399A (ru)
MY (1) MY127530A (ru)
NL (2) NL300258I2 (ru)
NO (5) NO313226B1 (ru)
PT (2) PT1174135E (ru)
RU (5) RU2198682C2 (ru)
SK (2) SK287351B6 (ru)
TW (2) TW438587B (ru)
ZA (1) ZA965190B (ru)

Families Citing this family (262)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
HUP9601808A3 (en) * 1995-07-03 2000-06-28 Sankyo Co Treatment of arteriosclerosis and xanthoma
IL122191A0 (en) 1995-08-10 1998-04-05 Warner Lambert Co Pharmaceutical compositions containing substituted benzopyrans
GB9600464D0 (en) * 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
EP1813286A3 (en) 1996-04-05 2008-04-16 Takeda Pharmaceutical Company Limited Pharmaceutical composition containing a compound having angiotensin II antagonistic activity in combination with another compound
EP0930076B1 (en) 1996-07-15 2004-12-01 Sankyo Company Limited Pharmaceutical compositions comprising CS-866 and insulin resistance improving agents and their use for the treatment of arteriosclerosis and xanthoma
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
US20010049380A1 (en) * 1997-06-18 2001-12-06 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and sulphonylurea
AU778947B2 (en) * 1997-06-18 2004-12-23 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and metformin
DE122007000054I1 (de) * 1997-06-18 2007-12-13 Smithkline Beecham Plc Behandlung der Diabetes mit Thiazolidindione und metformin
AU783539B2 (en) * 1997-06-18 2005-11-10 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and sulphonylurea
SK286028B6 (sk) * 1997-06-18 2008-01-07 Smithkline Beecham Plc Farmaceutický prostriedok a jeho použitie
IL133138A0 (en) * 1997-06-18 2001-03-19 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor
US20020028768A1 (en) * 1997-06-18 2002-03-07 Smithkline Beecham P.L.C. Treatment of diabetes with rosiglitazone and insulin
US20020016287A1 (en) * 1997-07-18 2002-02-07 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
GB9715298D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
GB9715306D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
GB9715295D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
AU782419B2 (en) * 1997-07-18 2005-07-28 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
NZ503796A (en) * 1997-10-20 2001-11-30 Dainippon Pharmaceutical Co Fast-dissolving pharmaceutical composition comprising micronised (R)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone (AS-3201)
US6583157B2 (en) 1998-01-29 2003-06-24 Tularik Inc. Quinolinyl and benzothiazolyl modulators
ATE413386T1 (de) 1998-01-29 2008-11-15 Amgen Inc Ppar-gamma modulatoren
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US7105552B2 (en) * 1998-05-08 2006-09-12 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
US6329403B1 (en) * 1998-06-30 2001-12-11 Takeda Chemical Industries, Ltd. Pharmaceutical composition for the treatment of diabetes
JP2000080047A (ja) * 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
DK0974356T3 (da) * 1998-07-15 2003-10-27 Merck Sante Sas Tabletter omfattende en kombination af metformin og glibenclamid
US6376549B1 (en) * 1998-09-17 2002-04-23 Akesis Pharmaceuticals, Inc. Metforimin-containing compositions for the treatment of diabetes
BR9915820A (pt) 1998-10-29 2001-10-30 Univ Texas Uso clìnico de tiazolidinadionas sozinhas ou emconjunto com outros agentes para bloquear asações mediadas pela oxitocina, tal comocontrações uterinas em parto prematuro oulactação
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
AR023700A1 (es) * 1998-11-12 2002-09-04 Smithkline Beecham Plc Un procedimiento para preparar una composicion farmaceutica que comprende un sensibilizador de insulina
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
PT1131070E (pt) * 1998-11-12 2008-11-19 Smithkline Beecham Plc Composição farmacêutica para libertação modificada de um sensibilizador à insulina e de outro agente antidiabético
AP1692A (en) * 1998-11-12 2006-12-12 Smithkline Beecham Plc Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent.
US6958324B2 (en) * 1998-12-02 2005-10-25 Inotek Pharmaceuticals Corporation Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
US20080269265A1 (en) * 1998-12-22 2008-10-30 Scott Miller Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
BR9917005A (pt) * 1998-12-24 2002-04-02 Metabasis Therapeutics Inc Combinação de inibidores de fbpase e sensibilizadores de insulina para o tratamento de diabete
US6756360B1 (en) 1998-12-24 2004-06-29 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
JP4799720B2 (ja) * 1999-01-29 2011-10-26 武田薬品工業株式会社 コーティング処理を施した打錠用杵
DE60039410D1 (de) * 1999-01-29 2008-08-21 Takeda Pharmaceutical Verdichtungshammer mit beschichtungsbehandlung
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
MXPA01009893A (es) * 1999-04-01 2003-07-28 Esperion Therapeutics Inc Compuestos con eter, composiciones y usos de estos.
US7407978B2 (en) * 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
JP2000355550A (ja) * 1999-04-14 2000-12-26 Takeda Chem Ind Ltd ケトーシス改善剤
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
KR100744359B1 (ko) * 1999-04-23 2007-07-30 스미스클라인비이참피이엘시이 티아졸리딘디온 유도체 및 항당뇨병제로서 그의 용도
GB9910693D0 (en) * 1999-05-07 1999-07-07 Univ Liverpool A compound for use in medicine
US6214842B1 (en) * 1999-05-12 2001-04-10 Michael S. Malamas Amino-thiazolidinediones useful in the treatment of insulin resistance and hyperglycemia
AU770870B2 (en) * 1999-06-18 2004-03-04 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
DK1133312T3 (da) * 1999-06-21 2008-01-02 Lilly Co Eli Synergistisk anvendelse af thiazolidindioner med glucagonlignende peptid-1 og agonister deraf til behandling af ikke-insulinafhængig diabetes
AU5760900A (en) * 1999-06-25 2001-01-31 Minimed, Inc. Multiple agent diabetes therapy
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
AU779730B2 (en) * 1999-06-30 2005-02-10 Amgen, Inc. Compounds for the modulation of PPARgamma activity
IL147308A0 (en) * 1999-06-30 2002-08-14 Tularik Inc Compounds for the modulation of pparγ activity and pharmaceutical compositions containing the same
US6878749B2 (en) * 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
CO5200844A1 (es) * 1999-09-17 2002-09-27 Novartis Ag Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes
AU2005200818B2 (en) * 1999-09-17 2008-07-17 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
AU780855B2 (en) * 1999-10-06 2005-04-21 Kurokawa, Kiyoshi Carbonyl stress-decreasing agent
WO2001026639A2 (en) * 1999-10-08 2001-04-19 Novartis Ag Pharmaceutical composition of ateglinide and another antidiabeticagent
US6274622B1 (en) * 1999-10-27 2001-08-14 Frederick H. Hausheer Method of treating diabetic ophthalmopathy
MXPA02004282A (es) 1999-11-03 2003-02-17 Squibb Bristol Myers Co Metodo para tratar la diabetes.
US6586438B2 (en) * 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
MY125516A (en) * 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
US6575997B1 (en) 1999-12-23 2003-06-10 Endovascular Technologies, Inc. Embolic basket
US6402771B1 (en) 1999-12-23 2002-06-11 Guidant Endovascular Solutions Snare
US6660021B1 (en) 1999-12-23 2003-12-09 Advanced Cardiovascular Systems, Inc. Intravascular device and system
GB9930688D0 (en) * 1999-12-24 2000-02-16 Smithkline Beecham Plc Novel method of treatment
AU2382601A (en) * 1999-12-24 2001-07-09 Smithkline Beecham Plc Novel method of treatment
US7918820B2 (en) 1999-12-30 2011-04-05 Advanced Cardiovascular Systems, Inc. Device for, and method of, blocking emboli in vessels such as blood arteries
US6695813B1 (en) 1999-12-30 2004-02-24 Advanced Cardiovascular Systems, Inc. Embolic protection devices
US6540722B1 (en) 1999-12-30 2003-04-01 Advanced Cardiovascular Systems, Inc. Embolic protection devices
US20010036479A1 (en) 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
AU2001229601A1 (en) * 2000-01-24 2001-07-31 Inotek Corporation Method and composition for modulating an immune response
US6540982B1 (en) * 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
US20030060488A1 (en) * 2000-02-10 2003-03-27 Yasuo Sugiyama Drug comprising combination
EP1295609A4 (en) * 2000-02-24 2004-11-03 Takeda Chemical Industries Ltd MEDICINES WITH MIXED ACTIVE SUBSTANCES
US6296874B1 (en) * 2000-05-01 2001-10-02 Aeropharm Technology Incorporated Core formulation comprising troglitazone and abiguanide
US6524621B2 (en) 2000-05-01 2003-02-25 Aeropharm Technology Inc. Core formulation
US6461639B2 (en) 2000-05-01 2002-10-08 Aeropharm Technology, Inc. Core formulation
US6548049B1 (en) * 2000-05-01 2003-04-15 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6451342B2 (en) * 2000-05-01 2002-09-17 Aeropharm Technology Incorporated Core formulation comprised of troglitazone and a biguanide
US6610272B1 (en) * 2000-05-01 2003-08-26 Aeropharm Technology Incorporated Medicinal aerosol formulation
AU6118001A (en) 2000-05-03 2001-11-12 Tularik Inc Combination therapeutic compositions and methods of use
US6270797B1 (en) * 2000-05-18 2001-08-07 Usv Limited Sustained release pharmaceutical composition containing glipizide and method for producing same
US6939362B2 (en) * 2001-11-27 2005-09-06 Advanced Cardiovascular Systems, Inc. Offset proximal cage for embolic filtering devices
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
US7563774B2 (en) 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
US6964670B1 (en) 2000-07-13 2005-11-15 Advanced Cardiovascular Systems, Inc. Embolic protection guide wire
AR033390A1 (es) * 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
US20060089389A1 (en) * 2000-08-22 2006-04-27 Malcolm Allison Combination
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
CA2424060A1 (en) * 2000-10-12 2003-03-31 Nissan Chemical Industries, Ltd. Preventives and remedies for complications of diabetes
US6537294B1 (en) 2000-10-17 2003-03-25 Advanced Cardiovascular Systems, Inc. Delivery systems for embolic filter devices
US6893451B2 (en) 2000-11-09 2005-05-17 Advanced Cardiovascular Systems, Inc. Apparatus for capturing objects beyond an operative site utilizing a capture device delivered on a medical guide wire
US6506203B1 (en) 2000-12-19 2003-01-14 Advanced Cardiovascular Systems, Inc. Low profile sheathless embolic protection system
PL362687A1 (en) 2001-01-12 2004-11-02 Sun Pharmaceutical Industries Limited Spaced drug delivery system
US6852694B2 (en) 2001-02-21 2005-02-08 Medtronic Minimed, Inc. Stabilized insulin formulations
ES2240657T3 (es) 2001-02-28 2005-10-16 Pfizer Products Inc. Compuestos de sulfonilpiridazinona utiles como inhibidores de aldosa reductasa.
JP2004531487A (ja) * 2001-03-02 2004-10-14 リヒトヴエル・フアルマ・アクチエンゲゼルシヤフト 糖尿病治療剤
KR200249057Y1 (ko) * 2001-03-22 2001-10-19 김진환 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
SK11852003A3 (sk) 2001-03-30 2004-07-07 Pfizer Products Inc. Derivát pyridazinónu ako inhibítor aldózreduktázy a farmaceutický prostriedok, ktorý ho obsahuje
CN1499971A (zh) * 2001-04-03 2004-05-26 ֮����ҩ��ʽ���� 芳基乙烯磺酰胺衍生物的新用途
WO2002080887A2 (en) * 2001-04-10 2002-10-17 Sun Pharmaceutical Industries Limited Timed pulse release composition
SE0101982D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
JP2002360666A (ja) * 2001-06-11 2002-12-17 Takeda Chem Ind Ltd コバルト合金を用いた打錠用杵臼
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
US6599307B1 (en) 2001-06-29 2003-07-29 Advanced Cardiovascular Systems, Inc. Filter device for embolic protection systems
US7338510B2 (en) 2001-06-29 2008-03-04 Advanced Cardiovascular Systems, Inc. Variable thickness embolic filtering devices and method of manufacturing the same
AU2001273310B2 (en) * 2001-07-10 2004-10-07 Kos Life Sciences, Inc. A core formulation
MXPA04000180A (es) * 2001-07-10 2004-11-22 Kos Life Sciences Inc Formulacion de nucleo que comprende hidrocloruro de pioglitazona y una biguanida.
US6638294B1 (en) 2001-08-30 2003-10-28 Advanced Cardiovascular Systems, Inc. Self furling umbrella frame for carotid filter
US6592606B2 (en) 2001-08-31 2003-07-15 Advanced Cardiovascular Systems, Inc. Hinged short cage for an embolic protection device
US8262689B2 (en) 2001-09-28 2012-09-11 Advanced Cardiovascular Systems, Inc. Embolic filtering devices
US7163952B2 (en) 2001-12-03 2007-01-16 Japan Tobacco Inc. Azole compound and medicinal use thereof
US7241304B2 (en) 2001-12-21 2007-07-10 Advanced Cardiovascular Systems, Inc. Flexible and conformable embolic filtering devices
DE10200138A1 (de) * 2002-01-04 2003-07-17 Karl Winkler Kombination von einem PPAR-Agonisten mit PPAR-alpha Aktivität mit einem Induktor des LDL-Rezeptors
TWI327462B (en) * 2002-01-18 2010-07-21 Sumitomo Chemical Co Condensed heterocyclic sulfonyl urea compound, a herbicide containing the same, and a method for weed control using the same
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US20030187074A1 (en) * 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes
TW200305415A (en) * 2002-03-22 2003-11-01 Novartis Ag Combination of organic compounds
AU2003235120A1 (en) * 2002-04-26 2003-11-10 Takeda Chemical Industries, Ltd. Screening method
US20070264348A1 (en) * 2002-05-24 2007-11-15 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
AU2002356419A1 (en) 2002-06-17 2003-12-31 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
US6887258B2 (en) 2002-06-26 2005-05-03 Advanced Cardiovascular Systems, Inc. Embolic filtering devices for bifurcated vessels
US7172614B2 (en) 2002-06-27 2007-02-06 Advanced Cardiovascular Systems, Inc. Support structures for embolic filtering devices
WO2004012715A1 (en) 2002-08-02 2004-02-12 Penwest Pharmaceuticals Company Sustained release formulations of metformin
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
EP1539144B1 (en) 2002-09-20 2014-12-24 Andrx Labs Llc Multistage formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7252675B2 (en) 2002-09-30 2007-08-07 Advanced Cardiovascular, Inc. Embolic filtering devices
US7331973B2 (en) 2002-09-30 2008-02-19 Avdanced Cardiovascular Systems, Inc. Guide wire with embolic filtering attachment
UA80991C2 (en) * 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
US20040088000A1 (en) 2002-10-31 2004-05-06 Muller Paul F. Single-wire expandable cages for embolic filtering devices
DE10252666A1 (de) * 2002-11-11 2004-08-05 Grünenthal GmbH N-Piperidyl-cyclohexan-Derivate
IN192749B (ru) * 2002-11-15 2004-05-15 Ranbaxy Lab Ltd
DE10261067A1 (de) * 2002-12-24 2004-08-05 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Cholesterinsenkendes Mittel, enthaltend eine n-3-Fettsäure
AU2004205642C1 (en) 2003-01-14 2012-01-12 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
US6794401B2 (en) * 2003-01-17 2004-09-21 Bexel Pharmaceuticals, Inc. Amino acid phenoxy ethers
DE10302452B4 (de) * 2003-01-23 2005-02-24 Aventis Pharma Deutschland Gmbh Carbonylamino-substituierte Acyl-phenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
US7179941B2 (en) 2003-01-23 2007-02-20 Sanofi-Aventis Deutschland Gmbh Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use
MXPA05007883A (es) 2003-01-29 2005-09-21 Takeda Pharmaceutical Proceso para producir una preparacion recubierta.
US7572910B2 (en) * 2003-02-20 2009-08-11 Pfizer, Inc. Pyridazinone aldose reductase inhibitors
US8591540B2 (en) 2003-02-27 2013-11-26 Abbott Cardiovascular Systems Inc. Embolic filtering devices
WO2004108067A2 (en) * 2003-04-03 2004-12-16 Sun Pharmaceutical Industries Limited Programmed drug delivery system
MXPA05010945A (es) * 2003-04-09 2005-11-25 Japan Tobacco Inc Compuesto pentaciclico heteroaromatico y uso medicinal del mismo.
US7820158B2 (en) * 2003-04-10 2010-10-26 Surmodics, Inc. Ligand-coupled initiator polymers and methods of use
CA2524175C (en) * 2003-04-28 2016-06-14 Sankyo Company Limited Sugar intake-ability enhancer
EP1621210B1 (en) * 2003-04-28 2013-06-19 Daiichi Sankyo Company, Limited Adiponectin production enhancer
US20050059708A1 (en) * 2003-05-13 2005-03-17 Karel Pospisilik Processes for making thiazolidinedione derivatives and compounds thereof
US7230016B2 (en) * 2003-05-13 2007-06-12 Synthon Ip Inc. Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same
US20050004179A1 (en) * 2003-05-22 2005-01-06 Pedersen Ward A. Methods and materials for treating, detecting, and reducing the risk of developing Alzheimer's Disease
CA2530228A1 (en) * 2003-06-27 2005-01-06 Dr. Reddy's Research Foundation Compositions comprising balaglitazone and further antidiabetic compounds
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
WO2005012485A2 (en) * 2003-07-31 2005-02-10 Bayer Pharmaceuticals Corporation Methods for treating diabetes and related disorders using pde10a inhibitors
EP1510208A1 (en) * 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
CN1921881A (zh) * 2003-10-27 2007-02-28 因诺迪亚公司 羟基化氨基酸用于治疗糖尿病的用途
PL1677792T3 (pl) * 2003-10-31 2016-05-31 Takeda Pharmaceuticals Co Stały preparat zawierający pioglitazon, glimepiryd i ester polioksyetylenosorbitanu z kwasem tłuszczowym
US7892251B1 (en) 2003-11-12 2011-02-22 Advanced Cardiovascular Systems, Inc. Component for delivering and locking a medical device to a guide wire
WO2005065663A1 (en) * 2003-12-31 2005-07-21 Alpharma, Inc. Rosiglitazone and metformin formulations
WO2005065654A2 (en) * 2003-12-31 2005-07-21 Alpharma, Inc. Rosiglitazone formulations
US7360069B2 (en) * 2004-01-13 2008-04-15 Hewlett-Packard Development Company, L.P. Systems and methods for executing across at least one memory barrier employing speculative fills
TWI297606B (en) * 2004-01-16 2008-06-11 Nat Health Research Institutes Cancer therapy
JP4901218B2 (ja) * 2004-02-09 2012-03-21 あすか製薬株式会社 併用医薬
WO2005080387A2 (en) * 2004-02-20 2005-09-01 Synthon B.V. Processes for making pioglitazone and compounds of the processes
EP1734953A4 (en) * 2004-03-02 2008-08-20 Abeille Pharmaceuticals Inc CO-PR PARATIONS OF KITS OF BIOACTIVE AGENTS
US7678129B1 (en) 2004-03-19 2010-03-16 Advanced Cardiovascular Systems, Inc. Locking component for an embolic filter assembly
US7161756B2 (en) * 2004-05-10 2007-01-09 Tandberg Data Storage Asa Method and system for communication between a tape drive and an external device
CN1327840C (zh) * 2004-06-08 2007-07-25 天津药物研究院 一种药物组合物及其在制备用于治疗糖尿病中的应用
AU2005271526B2 (en) * 2004-08-03 2011-12-08 Emisphere Technologies, Inc. Antidiabetic oral insulin-biguanide combination
EP1796687A2 (en) * 2004-09-14 2007-06-20 Elixir Pharmaceuticals, Inc. Combination therapy for controlled carbohydrate digestion
MXPA04009236A (es) * 2004-09-23 2006-03-27 Jorge Luis Rosado Loria Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades.
JP2008019169A (ja) * 2004-10-25 2008-01-31 Osaka Univ 新規ｐｐａｒ調節剤およびそのスクリーニング方法
US20060089387A1 (en) * 2004-10-26 2006-04-27 Le Huang Stabilized pharmaceutical composition comprising antidiabetic agent
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
US9259305B2 (en) 2005-03-31 2016-02-16 Abbott Cardiovascular Systems Inc. Guide wire locking mechanism for rapid exchange and other catheter systems
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
GT200600218A (es) * 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
CN101217965B (zh) * 2005-07-07 2012-07-18 学校法人浦项工科大学校 葡萄糖吸收调节剂和用于治疗糖尿病或糖尿病并发症的方法
EP1906934A4 (en) * 2005-07-14 2012-03-07 Franco Folli DAILY DOSAGE SCHEME FOR THE TREATMENT OF DIABETES, OBESITY, METABOLIC SYNDROME AND POLYKYSTIC OVAIRE SYNDROME
CA2615975C (en) * 2005-07-22 2012-11-27 The Procter & Gamble Company Compositions for reducing the incidence of drug induced arrhythmia
MXPA05013220A (es) * 2005-12-06 2007-06-05 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus tipo 2.
MY149306A (en) 2005-12-22 2013-08-30 Takeda Pharmaceutical Solid preparation containing an insulin sensitizer
FR2896157B1 (fr) 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
WO2007105730A1 (ja) * 2006-03-13 2007-09-20 Kyowa Hakko Kogyo Co., Ltd. インスリン抵抗性改善剤
ES2397944T3 (es) 2006-03-16 2013-03-12 Metabolic Solutions Development Company Llc Análogos de tiazolidindiona
JP2009532372A (ja) * 2006-03-31 2009-09-10 ウェルスタット セラピューティクス コーポレイション 代謝障害の併用治療
AU2007235737B2 (en) * 2006-04-11 2011-12-08 Sorbwater Technology As Method for removal of materials from a liquid stream
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
AU2007265475B2 (en) 2006-06-26 2010-08-19 Amgen Inc. Methods for treating atherosclerosis
US7752724B2 (en) * 2006-06-27 2010-07-13 Lumino, Inc. Method of cutting blinds
WO2008026668A1 (fr) * 2006-08-31 2008-03-06 Daiichi Sankyo Company, Limited Composition médicale contenant un agent d'amélioration de la résistance à l'insuline
US20080182880A1 (en) * 2006-09-28 2008-07-31 Mailatur Sivaraman Mohan Pioglitazone composition
US8217025B2 (en) * 2006-11-17 2012-07-10 Harbor Therapeutics, Inc. Drug screening and treatment methods
EP2016076A2 (en) * 2007-01-22 2009-01-21 Teva Pharmaceutical Industries Ltd. Polymorphic forms of rosiglitazone hydrobromide and processes for preparation thereof
WO2008089521A1 (en) 2007-01-25 2008-07-31 Verva Pharmaceuticals Ltd Insulin sensitisers and methods of treatment
GEP20125410B (en) * 2007-02-01 2012-02-27 Takeda Pharmaceutical Solid preparation comprising alogliptin and pioglitazone
WO2008124122A1 (en) * 2007-04-09 2008-10-16 Scidose, Llc Combinations of statins and anti-obesity agent and glitazones
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
RU2492858C2 (ru) * 2007-04-11 2013-09-20 Омерос Корпорейшн Композиции и способы профилактики и лечения зависимостей
US8216209B2 (en) 2007-05-31 2012-07-10 Abbott Cardiovascular Systems Inc. Method and apparatus for delivering an agent to a kidney
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US7867273B2 (en) 2007-06-27 2011-01-11 Abbott Laboratories Endoprostheses for peripheral arteries and other body vessels
DK2489731T3 (en) 2007-07-26 2014-11-17 Amgen Inc Modified lecithin-cholesterol acyltransferase enzymes
KR101537830B1 (ko) * 2007-09-14 2015-07-17 메타볼릭 솔루션스 디벨롭먼트 컴퍼니, 엘엘씨 고혈압 치료용 티아졸리딘디온 유사체
WO2009038107A1 (ja) * 2007-09-21 2009-03-26 Kissei Pharmaceutical Co., Ltd. ２型糖尿病治療用の組合せ医薬
WO2009073627A1 (en) * 2007-11-30 2009-06-11 The Research Foundation Of State University Of New York Metabolic fuel switching biomarker
US8551524B2 (en) 2008-03-14 2013-10-08 Iycus, Llc Anti-diabetic combinations
EP2190417A2 (en) * 2008-03-26 2010-06-02 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions comprising insulin sensitizer and insulin secretagogue
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
PE20151924A1 (es) 2008-08-12 2016-01-13 Zinfandel Pharmaceuticals Inc Metodo de identificacion de factores de riesgo de la enfermedad
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
CN102348457A (zh) 2009-03-11 2012-02-08 奥默罗斯公司 预防和治疗成瘾的组合物和方法
US20110038848A1 (en) * 2009-08-12 2011-02-17 Melaleuca, Inc. Dietary supplement compositions for cardiovascular health
BR112012011237A2 (pt) 2009-11-13 2019-09-24 Univ Tokyo agente terapêutico e profilático para diabetes
KR101851130B1 (ko) * 2009-12-04 2018-04-23 센화 바이오사이언시즈 인코포레이티드 Ｃｋ2 억제제로서 피라졸로피리미딘 및 관련된 헤테로사이클
JP5634526B2 (ja) * 2009-12-15 2014-12-03 メタボリック ソリューションズ ディベロップメント カンパニー， エルエルシー 代謝性疾患を処置するためのｐｐａｒ温存チアゾリジンジオン塩
EP2512470B1 (en) * 2009-12-15 2016-11-30 Octeta Therapeutics, LLC Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases
JP2013523681A (ja) 2010-03-30 2013-06-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｇｌｔ２インヒビター及びｐｐａｒ−ガンマアゴニストを含む医薬組成物並びにその使用
BR112012025592A2 (pt) * 2010-04-06 2019-09-24 Arena Pharm Inc moduladores do receptor de gpr119 e o tratamento de distúrbios relacionados com os mesmos
RU2526153C2 (ru) * 2010-07-15 2014-08-20 Олег Ильич Эпштейн Способ повышения фармакологической активности действующего вещества лекарственного средства и фармацевтическая композиция
EP2611434A1 (en) 2010-09-01 2013-07-10 Lupin Limited Pharmaceutical composition comprising metformin and pioglitazone
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
SG188548A1 (en) 2010-09-22 2013-04-30 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
EA201391017A1 (ru) 2011-01-10 2014-04-30 Зинфандел Фармасьютикалз, Инк. Способы и готовые лекарственные формы для лечения болезни альцгеймера
RU2013135224A (ru) * 2011-01-20 2015-03-10 Бионевиа Фармасьютикалс Инк. Композиции с модифицированным высвобождением эпалрестата или его производных и способы их использования
WO2013034174A1 (en) 2011-09-06 2013-03-14 ZENTIVA Saglik Ürünleri Sanayi ve Ticaret A.S. Solid preparations of pioglitazone and glimepiride
BR112014010223B8 (pt) 2011-10-28 2021-02-23 Lumena Pharmaceuticals Llc uso de uma composição compreendendo inibidores de reciclagem de ácido de bílis e forma de dosagem pediátrica
EP3278796A1 (en) 2011-10-28 2018-02-07 Lumena Pharmaceuticals LLC Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
MX368200B (es) 2011-12-08 2019-09-24 Amgen Inc Proteinas de union al antigeno lecitin colesterol aciltransferasas humanas agonistas y su uso en terapia.
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
KR102272746B1 (ko) 2013-06-05 2021-07-08 보슈 헬스 아일랜드 리미티드 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법
AU2014331812B2 (en) 2013-10-09 2019-01-17 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
RU2572706C1 (ru) * 2014-06-30 2016-01-20 Олег Ильич Эпштейн Способ повышения фармакологической активности действующего вещества лекарственного средства и фармацевтическая композиция
DK3253382T3 (da) 2015-02-06 2022-02-14 Intercept Pharmaceuticals Inc Farmaceutiske sammensætninger til kombinationsterapi
KR102603199B1 (ko) 2015-06-22 2023-11-16 아레나 파마슈티칼스, 인크. Ｓ1ｐ1 수용체-관련 장애에서의 사용을 위한 (ｒ)-2-(7-(4-시클로펜틸-3-(트리플루오로메틸)벤질옥시)-1,2,3,4-테트라히드로시클로-펜타[ｂ]인돌-3-일)아세트산 (화합물 1)의 결정성 ｌ-아르기닌 염
EP3568134A1 (en) 2017-01-16 2019-11-20 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods and pharmaceutical compositions for reducing cd95- mediated cell motility
BR112020024762A2 (pt) 2018-06-06 2021-03-23 Arena Pharmaceuticals, Inc. métodos de tratamento de condições relacionadas ao receptor s1p1
EP3807895A1 (en) 2018-06-14 2021-04-21 AstraZeneca UK Limited Methods for lowering blood sugar with a metformin pharmaceutical composition
SG11202113155XA (en) 2019-05-30 2021-12-30 Intercept Pharmaceuticals Inc Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease
CN112869173A (zh) * 2021-01-18 2021-06-01 广州富诺营养科技有限公司 一种复合维生素矿物质制剂及其制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3454635A (en) 1965-07-27 1969-07-08 Hoechst Ag Benzenesulfonyl-ureas and process for their manufacture
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5728073A (en) * 1980-07-29 1982-02-15 Takeda Chem Ind Ltd Inhibitor for aldose reducing enzyme
US4863922A (en) 1984-12-12 1989-09-05 Merck & Co., Inc. Substituted aromatic sulfonamides as antiglaucoma agents, compositions and use
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
AU598366B2 (en) 1987-03-20 1990-06-21 Alcon Laboratories, Inc. Use of aldose reductase inhibitors to enhance insulin sensitivity in diabetes
DE3729209A1 (de) * 1987-09-01 1989-03-09 Boehringer Mannheim Gmbh Verwendung von bezafibrat zur behandlung von diabetes
ES2137915T3 (es) 1987-09-04 2000-01-01 Beecham Group Plc Derivados de tiazolidindiona sustituida.
US4895862A (en) 1989-04-21 1990-01-23 American Home Products Corp. Novel benzyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents
US5068342A (en) * 1989-10-27 1991-11-26 American Home Products Corporation 5-[(1- and 2-naphthalenyl)thio and sulfonyl]-2,4-thiazolidinediones and derivatives thereof
US5356913A (en) * 1990-02-09 1994-10-18 The Upjohn Company Use of insulin sensitizing agents to treat hypertension
JPH0466579A (ja) * 1990-07-04 1992-03-02 Yamanouchi Pharmaceut Co Ltd チアゾリジン誘導体
JPH0469383A (ja) * 1990-07-06 1992-03-04 Yamanouchi Pharmaceut Co Ltd 置換チアゾリジン誘導体
US5260275A (en) * 1990-08-14 1993-11-09 Amylin Pharmaceuticals, Inc. Hypoglycemics
CA2052014A1 (en) * 1990-10-19 1992-04-20 Henry Y. Pan Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor
JP2686861B2 (ja) * 1991-03-30 1997-12-08 キッセイ薬品工業株式会社 新規なベンジリデンコハク酸誘導体
EP0601001B1 (en) * 1991-08-26 1997-04-16 PHARMACIA & UPJOHN COMPANY Liquid food product containing 3-guanidinopropionic acid
JPH05202042A (ja) * 1992-01-24 1993-08-10 Sankyo Co Ltd 糖尿病性合併症治療剤
JPH07316144A (ja) * 1994-03-29 1995-12-05 Sankyo Co Ltd ジフェニルメチルピペラジン誘導体
TW403748B (en) * 1994-11-02 2000-09-01 Takeda Chemical Industries Ltd An oxazolidinedione derivative, its production and a pharmaceutical composition for lowering blood sugar and lipid in blood comprising the same
US5674900A (en) * 1995-06-06 1997-10-07 Shaman Pharmaceuticals, Inc. Terpenoid-type quinones for treatment of diabetes
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
HUP9601808A3 (en) * 1995-07-03 2000-06-28 Sankyo Co Treatment of arteriosclerosis and xanthoma
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6011049A (en) 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
GB9715298D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
US6001049A (en) * 1998-02-12 1999-12-14 Frey; Mark P. Light weight exercise apparatus

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LEFEVRE et al. Drugs. - 1992, 44, р.29-38. *
Клиническая эндокринология. Руководство для врачей/Под ред. Н.Т. Старковой. - М.: Медицина, 1991, с.236-239, 254-256. *

Also Published As

Publication number Publication date
SK287287B6 (sk) 2010-05-07
LU91298I2 (fr) 2007-02-20
RU2003130978A (ru) 2005-04-20
US6121295A (en) 2000-09-19
CN1212117C (zh) 2005-07-27
AR065389A2 (es) 2009-06-03
US6251924B1 (en) 2001-06-26
SK287351B6 (sk) 2010-08-09
US6080765A (en) 2000-06-27
FR09C0055I2 (fr) 2010-06-11
JPH10167986A (ja) 1998-06-23
AR061195A2 (es) 2008-08-13
US6133295A (en) 2000-10-17
EP0749751A2 (en) 1996-12-27
DK0861666T3 (da) 2004-03-08
ATE438397T1 (de) 2009-08-15
NO20021172L (no) 1996-12-23
ZA965190B (en) 1997-12-19
EP0861666A3 (en) 1999-02-10
CN1530105A (zh) 2004-09-22
CN1289082C (zh) 2006-12-13
US7842706B2 (en) 2010-11-30
DE122007000002I1 (de) 2012-03-08
US7538125B2 (en) 2009-05-26
US20020128289A1 (en) 2002-09-12
EP1174135B2 (en) 2016-09-14
PT861666E (pt) 2004-05-31
US20020042434A1 (en) 2002-04-11
US20040266830A1 (en) 2004-12-30
AU5603496A (en) 1997-01-09
HK1010484A1 (en) 1999-06-25
US20110034518A1 (en) 2011-02-10
US20030216443A1 (en) 2003-11-20
DE69631157D1 (de) 2004-01-29
JP3148973B2 (ja) 2001-03-26
NO962606D0 (no) 1996-06-19
CA2533845A1 (en) 1996-12-21
CZ292093B6 (cs) 2003-07-16
DE122007000002I2 (de) 2012-03-08
US6239153B1 (en) 2001-05-29
EP2289556A2 (en) 2011-03-02
US6150384A (en) 2000-11-21
RU2323004C2 (ru) 2008-04-27
NO20004345D0 (no) 2000-09-01
US6218409B1 (en) 2001-04-17
US6172090B1 (en) 2001-01-09
EP1174135A2 (en) 2002-01-23
US6211207B1 (en) 2001-04-03
CA2179584C (en) 2007-04-24
DE122009000064I1 (de) 2011-12-01
CY2009018I2 (el) 2010-07-28
HUP9601698A2 (hu) 1997-05-28
DE69631157T2 (de) 2004-09-09
US6274605B1 (en) 2001-08-14
JP2007191494A (ja) 2007-08-02
NO2007001I1 (no) 2007-01-29
HU9601698D0 (en) 1996-08-28
US6169100B1 (en) 2001-01-02
US6288090B1 (en) 2001-09-11
KR20080005162A (ko) 2008-01-10
RU2286148C2 (ru) 2006-10-27
EP2292268A1 (en) 2011-03-09
JP4809806B2 (ja) 2011-11-09
US20020123512A1 (en) 2002-09-05
JP3973280B2 (ja) 2007-09-12
US20070203198A1 (en) 2007-08-30
DK1174135T3 (da) 2009-12-07
US20050054685A1 (en) 2005-03-10
KR20070081135A (ko) 2007-08-16
CY2424B1 (en) 2004-11-12
EP0861666B1 (en) 2003-12-17
NO2007007I2 (no) 2009-10-05
US6169099B1 (en) 2001-01-02
NO2007007I1 (no) 2007-06-18
EP0749751A3 (en) 1997-04-16
NO20021172D0 (no) 2002-03-08
SK79496A3 (en) 1997-01-08
US7144900B2 (en) 2006-12-05
US6133293A (en) 2000-10-17
US20090246232A1 (en) 2009-10-01
US6323225B1 (en) 2001-11-27
CZ181196A3 (en) 1997-01-15
MX9602399A (es) 1997-02-28
US6211205B1 (en) 2001-04-03
EP1764110A1 (en) 2007-03-21
MY127530A (en) 2006-12-29
US6599923B2 (en) 2003-07-29
US6150383A (en) 2000-11-21
US6166043A (en) 2000-12-26
US5952356A (en) 1999-09-14
NO2007001I2 (no) 2011-03-14
HUP9601698A3 (en) 2000-09-28
US20020002186A1 (en) 2002-01-03
KR970000233A (ko) 1997-01-21
LU91606I2 (fr) 2009-11-09
TW438587B (en) 2001-06-07
US6214848B1 (en) 2001-04-10
ES2327383T3 (es) 2009-10-29
FR09C0055I1 (ru) 2009-04-12
US6277869B1 (en) 2001-08-21
CA2531834C (en) 2006-12-05
US6384062B1 (en) 2002-05-07
US6911459B2 (en) 2005-06-28
CY2007001I2 (el) 2009-11-04
US6156773A (en) 2000-12-05
NO314065B1 (no) 2003-01-27
CN1145783A (zh) 1997-03-26
NO20004345L (no) 1996-12-23
US6211206B1 (en) 2001-04-03
TWI238064B (en) 2005-08-21
NO962606L (no) 1996-12-23
DE69637988D1 (de) 2009-09-17
EP0861666A2 (en) 1998-09-02
HK1041203A1 (en) 2002-07-05
CY2009018I1 (el) 2010-07-28
CA2531834A1 (en) 1996-12-21
CA2179584A1 (en) 1996-12-21
ES2212208T3 (es) 2004-07-16
EP1174135A3 (en) 2002-06-19
NO317341B1 (no) 2004-10-11
NL300432I2 (en) 2010-04-01
EP2289556A3 (en) 2011-03-09
CY2007001I1 (el) 2009-11-04
US5965584A (en) 1999-10-12
US6271243B1 (en) 2001-08-07
RU2198682C2 (ru) 2003-02-20
US6329404B1 (en) 2001-12-11
US6174904B1 (en) 2001-01-16
US6232330B1 (en) 2001-05-15
CZ291624B6 (cs) 2003-04-16
ATE256463T1 (de) 2004-01-15
US6166042A (en) 2000-12-26
US6303640B1 (en) 2001-10-16
US6172089B1 (en) 2001-01-09
AR091289A2 (es) 2015-01-28
AR005641A1 (es) 1999-07-14
EP1174135B1 (en) 2009-08-05
RU2327455C2 (ru) 2008-06-27
CN1530106A (zh) 2004-09-22
JPH0967271A (ja) 1997-03-11
NO313226B1 (no) 2002-09-02
US6225326B1 (en) 2001-05-01
NL300432I1 (en) 2010-03-01
HK1041203B (zh) 2009-09-25
PT1174135E (pt) 2009-08-31
US6103742A (en) 2000-08-15
NL300258I2 (nl) 2007-05-01
US6121294A (en) 2000-09-19
EP1174135B9 (en) 2009-12-16
CA2533845C (en) 2012-10-09
ES2327383T5 (es) 2017-03-13
NL300258I1 (nl) 2007-04-02
AU723097B2 (en) 2000-08-17
CY2608B2 (en) 2010-04-28

Similar Documents

Publication Publication Date Title
RU2223760C2 (ru) Способы профилактики и лечения, применение усилителей чувствительности к инсулину
RU2002104459A (ru) Способы профилактики и лечения, применение усилителей чувствительности к инсулину
RU96111958A (ru) Фармацевтическая композиция
CA1331020C (en) Medicament with improved penetration of the tissue membrane
RU2227800C2 (ru) Новые эффекторы дипептидилпептидазы iv
JP4875491B2 (ja) メトホルミンとスタチンとの組み合わせを含む医薬組成物
AU2006222060B2 (en) Roflumilast for the treatment of diabetes mellitus
RU2001118826A (ru) N-замещенные 2-цианопирролидины
RU95118725A (ru) Производные оксазолидиндиона, их получение и фармацевтическая композиция
RU2009102515A (ru) Конденсированные циклические соединения
JP2007528886A (ja) 肥満の治療又は予防用のメトホルミン及びオルリスタットの使用
CA2377661A1 (en) Use of fatty acid derivative for the treatment of external secretion disorders
KR950704330A (ko) 면역억제제로서의 라파마이신 카보네이트 에스테르(Rapamycin carbonate esters as immunosuppressant agents)
DE69405425D1 (de) Oxazolidinedione-Derivate, ihre Herstellung und ihre Verwendung zur Hemmung Zucker und Lipid in Blut
RU2006143666A (ru) Фармацевтические композиции в виде раствора, содержащие 17-aag
WO2018148206A1 (en) Treatment of diabetes and associated metabolic conditions with epigenetic modulators
KR950702997A (ko) 포스폰산 디에스테르 유도체(phosphonic diester derivative)
CA2042113A1 (en) Spiro-isoquinoline-pyrrolidines and analogs thereof useful as aldose reductase inhibitors
AU601326B2 (en) 3-substituted-2-oxindole-1-carboxamides for suppressing t-cell function
BR0311834A (pt) Composto, composição farmacêutica, métodos para mudular um receptor ativado por proliferador de peroxisoma, para tratar e prevenir diabetes mellitus em um mamìfero e para tratar sìndrome x em um mamìfero, e, uso de um composto ou seu sal farmaceuticamente aceitável
AU637745B2 (en) Use of tenidap to inhibit the activity of myeloperoxidase
CA2445651A1 (en) Cathartic composition comprising halogenated prostaglandin derivatives
CA1313139C (en) D1-5-[(2-benzyl-3,4-dihydro-2h-benzopyran-6-yl)methyl] thiazolidine-2,4-dione as an anti-atherosclerosis agent
US6117909A (en) Methods of using sulfamic acid derivatives for lowering serum or plasma level of Lp(a)
RU2005130005A (ru) 1,3-замещенные циклоалкильные производные с кислотными, чаще всего гетероциклическими группами, способы их получения и их применение в качестве лекарственных средств

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner
MF42 Invention patent partially invalidated

Effective date: 20071205